In Stock | Sacubitril impurity references

Sacubitril Valsartan Sodium Tablets is the world‘s first commercially available angiotensin receptor-neprilysin inhibitor (ARNI). It was approved for marketing in 2017 by the National Medical Products Administration (NMPA) of China under the trade name "Entresto". As a medication for chronic heart failure, it received further approval from the NMPA in June 2021 for the treatment of primary hypertension.

Heart failure is a condition caused by various factors that lead to structural or functional abnormalities of the heart, resulting in impaired ventricular systolic and diastolic function. This ultimately means the heart cannot meet the body‘s basic metabolic needs. Mortality and hospitalization rates among heart failure patients remain persistently high. With the intensification of population aging and the rising incidence of cardiovascular diseases, heart failure and hypertension have become significant public health problems posing a serious threat to human health.

Sacubitril Valsartan Sodium is a compound preparation consisting of sacubitril and the angiotensin II receptor blocker (ARB) valsartan. It is a representative drug of the ARNI class. It has been recommended by various Chinese guidelines, including the "Chinese Guidelines for the Prevention and Treatment of Hypertension (2024)", the "Chinese Expert Consensus on the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction (2023)", and the "National Guidelines for Heart Failure (2023)", establishing it as a fundamental medication in the treatment of heart failure and hypertension.

Sacubitril is a neprilysin inhibitor. It works by inhibiting neprilysin, the enzyme responsible for degrading natriuretic peptides, thereby increasing the levels of beneficial natriuretic peptides in the body. These peptides help dilate blood vessels, promote diuresis and natriuresis, and inhibit cardiac fibrosis. Furthermore, through its synergistic action with valsartan, Sacubitril Valsartan Sodium demonstrates significant advantages in lowering blood pressure and improving cardiac function.

Strengthening quality control over Sacubitril impurities during drug development, optimizing synthesis processes, and minimizing impurity generation are crucial steps in ensuring patient medication safety.

 SZEB currently supplies Sacubitril impurity reference standards​from stock, available in various specifications. These include a series of nitroso-Sacubitril impurities, various stereoisomers (such as (2R,4S) and (2R,4R) configurations), specific intermediate impurities, and more, catering to diverse experimental requirements.

Visit our official website for more detailed impurity information: ​​www-ex-biotech.com . Inquiry hotline: 0755-23051186​​.